Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
05 Agosto 2024 - 3:06PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
Report of
Foreign Private Issuer
Pursuant to
Rule 13a-16 or 15d-16
of the
Securities Exchange Act of 1934
For the month of August 2024
Commission File Number: 001-40299
Achilles Therapeutics plc
(Exact name of registrant as specified in its charter)
245
Hammersmith Road
London W6 8PW
United Kingdom
Tel: +44
(0)20 8154 4600
(Address, Including Zip Code, and Telephone Number, Including Area Code, of Registrants Principal Executive
Offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form
20-F ☒ Form 40-F ☐
Information Contained in this Report on Form 6-K
Karl Peggs, Chief Medical Officer of Achilles Therapeutics plc (Achilles Therapeutics or the Company), will be stepping down as Chief
Medical Officer (CMO) of the Company, effective August 6, 2024 to focus more time on his expanding roles as Director of Research at UCLH and Director of the National Institute for Health and Care Research (NIHR) UCLH Biomedical Research Centre
(BRC). He will remain as an advisor to Achilles Therapeutics.
Matilde Saggese, MD, has been appointed as Interim CMO. Matilde has served as Vice
President and Medical Director of Achilles Therapeutics since March 2021.
***
This Report on Form 6-K is incorporated by reference into the Companys Registration Statements on Forms F-3 (File No. 333-268239) and S-8 (File Nos. 333-278501, 333-270344, 333-263220, and 333-255063) to the extent not superseded by
information subsequently filed or furnished (to the extent the Company expressly states that it incorporates such furnished information by reference) by the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of
1934, as amended.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
ACHILLES THERAPEUTICS PLC |
|
|
|
|
Date: August 5, 2024 |
|
|
|
By: |
|
/s/ Robert Coutts |
|
|
|
|
|
|
Robert Coutts |
|
|
|
|
|
|
Chief Financial Officer |
Achilles Therapeutics (NASDAQ:ACHL)
Gráfica de Acción Histórica
De Ago 2024 a Sep 2024
Achilles Therapeutics (NASDAQ:ACHL)
Gráfica de Acción Histórica
De Sep 2023 a Sep 2024